

UnitedHealthcare Pharmacy  
Clinical Pharmacy Programs

Program Number	2025 P 2172-14
Program	Prior Authorization/Medical Necessity
Medications	*Nucala® (mepolizumab) * This program applies to the prefilled autoinjector and prefilled syringe formulations.
P&T Approval Date	8/2019, 4/2020, 8/2020, 3/2021, 6/2021, 9/2021, 11/2021, 2/2022, 6/2022, 6/2023, 7/2023, 7/2024, 7/2025, 12/2025
Effective Date	3/1/2026

**1. Background:**

Nucala (mepolizumab) is an interleukin-5 receptor antagonist indicated for add-on maintenance treatment of patients aged 6 years and older with severe asthma and with an eosinophilic phenotype, for add-on maintenance treatment of adult patients 18 years and older with chronic rhinosinusitis with nasal polyps (CRSwNP), the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), for add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype, and the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for ≥6 months without an identifiable non-hematologic secondary cause<sup>1</sup>.

Limitations of use:

Nucala is not for relief of acute bronchospasm of status asthmaticus.

**2. Coverage Criteria<sup>a</sup>:**

**A. Eosinophilic granulomatosis with polyangiitis (EGPA)**

**1. Initial Authorization**

a. Nucala will be approved based on **one** of the following criteria:

(1) **All** of the following:

(a) Patient has been established on therapy with Nucala under an active UnitedHealthcare medical benefit prior authorization for the treatment of EGPA

-AND-

(b) Documentation of positive clinical response to Nucala therapy as demonstrated by at least **one** of the following:

- i. Reduction in the frequency and/or severity of relapses
- ii. Reduction or discontinuation of doses of corticosteroids and/or immunosuppressant
- iii. Disease remission
- iv. Reduction in severity or frequency of EGPA-related symptoms

-AND-

(c) Patient is not receiving Nucala in combination with **any** of the following for treatment of the same indication:

- i. Anti-interleukin 5 therapy [e.g., Cinqair (reslizumab), Fasentra (benralizumab)]
- ii. Anti-IgE therapy [e.g., Xolair (omalizumab)]
- iii. Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
- iv. Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

-AND-

(d) Prescribed by **one** of the following:

- i. Pulmonologist
- ii. Rheumatologist
- iii. Allergist
- iv. Immunologist

-OR-

(2) **All** of the following:

(a) Diagnosis of relapsing or refractory EGPA as defined by **all** of the following:

- i. Diagnosis of EGPA

-AND-

- ii. Past medical history or presence of asthma

-AND-

iii. Presence of at least **two** of the following characteristics typical of EGPA:

- Histopathological evidence of:
  - Eosinophilic vasculitis
  - Perivascular eosinophilic infiltration
  - Eosinophil-rich granulomatous inflammation
- Neuropathy, mono or poly (motor deficit or nerve conduction abnormality)
- Pulmonary infiltrates, non-fixed
- Sino-nasal abnormality
- Cardiomyopathy (established by echocardiography or MRI)
- Glomerulonephritis (hematuria, red cell casts, proteinuria)
- Alveolar hemorrhage

- Palpable purpura
- Anti-neutrophil cytoplasmic antibody (ANCA) positive

-AND-

- iv. History of relapsing or refractory disease defined as **one** of the following:
- Relapsing disease as defined as a past history (within the past 2 years) of at least one EGPA relapse (requiring additional or dose escalation of corticosteroids or immunosuppressant, or hospitalization)
  - Refractory disease as defined as failure to attain remission within the prior 6 months following induction treatment with standard therapy regimens

-AND-

- (b) Patient is currently taking standard therapy [i.e., systemic glucocorticoids (e.g., prednisone, methylprednisolone) with or without immunosuppressive therapy (e.g., cyclophosphamide, rituximab)]

-AND-

- (c) Patient is not receiving Nucala in combination with **any** of the following for treatment of the same indication:
- i. Anti-interleukin-5 therapy [e.g., Cinqair (reslizumab), Fasenra(benralizumab)]
  - ii. Anti-IgE therapy [e.g., Xolair (omalizumab)]
  - iii. Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]
  - iv. Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

-AND-

- (d) Prescribed by **one** of the following:
- i. Pulmonologist
  - ii. Rheumatologist
  - iii. Allergist
  - iv. Immunologist

**Authorization will be issued for 12 months.**

## **2. Reauthorization**

- a. **Nucala** will be approved based on **both** of the following criteria:

- (1) Documentation of positive clinical response to Nucala therapy as demonstrated by at least **one** of the following:

- (a) Reduction in the frequency and/or severity of relapses
- (b) Reduction or discontinuation of doses of corticosteroids and/or immunosuppressant
- (c) Disease remission
- (d) Reduction in severity or frequency of EGPA-related symptoms

-AND-

(2) Patient is not receiving Nucala in combination with **any** of the following for treatment of the same indication:

- (a) Anti-interleukin-5 therapy [e.g., Cinqair (reslizumab), Fasenra (benralizumab)]
- (b) Anti-IgE therapy [e.g., Xolair (omalizumab)]
- (c) Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]
- (d) Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

**Authorization will be issued for 12 months.**

## **B. Severe Asthma**

### **1. Initial Authorization**

a. **Nucala** will be approved based on **one** of the following criteria:

(1) **All** of the following:

- (a) Patient has been established on therapy with Nucala under an active UnitedHealthcare medical benefit prior authorization for the treatment of severe asthma

-AND-

(b) Documentation of positive clinical response to Nucala therapy as demonstrated by at least **one** of the following:

- i. Reduction in the frequency of exacerbations
- ii. Decreased utilization of rescue medications
- iii. Increase in percent predicted FEV1 from pretreatment baseline
- iv. Reduction in severity or frequency of asthma-related symptoms (e.g., wheezing, shortness of breath, coughing, etc.)
- v. Reduction in oral corticosteroid requirements

-AND-

(c) Nucala is being used in combination with an inhaled corticosteroid (ICS)-containing maintenance medication [e.g., Advair/AirDuo (fluticasone/salmeterol), Breo Ellipta (fluticasone furoate/vilanterol),

Symbicort (budesonide/ formoterol), Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)].

**-AND-**

(d) Patient is not receiving Nucala in combination with **any** of the following for treatment of the same indication:

- i. Anti-interleukin-5 therapy [e.g., Cinqair (reslizumab), Fasenna (benralizumab)]
- ii. Anti-IgE-therapy [e.g., Xolair (omalizumab)]
- iii. Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]
- iv. Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

**-AND-**

(e) Prescribed by **one** of the following:

- i. Pulmonologist
- ii. Allergist
- iii. Immunologist

**-OR-**

(2) **All** of the following:

(a) Diagnosis of severe asthma

**-AND-**

(b) Classification of asthma as uncontrolled or inadequately controlled as defined by at least **one** of the following:

- i. Poor symptom control (e.g., Asthma Control Questionnaire [ACQ] score consistently greater than 1.5 or Asthma Control Test [ACT] score consistently less than 20)
- ii. Two or more bursts of systemic corticosteroids for at least 3 days each in the previous 12 months
- iii. Asthma-related emergency treatment (e.g., emergency room visit, hospital admission, or unscheduled physician's office visit for nebulizer or other urgent treatment)
- iv. Airflow limitation (e.g., after appropriate bronchodilator withhold forced expiratory volume in 1 second [FEV1] less than 80% predicted [in the face of reduced FEV1/forced vital capacity [FVC] defined as less than the lower limit of normal])
- v. Patient is currently dependent on oral corticosteroids for the treatment of asthma

**-AND-**

- (c) Submission of medical records (e.g., chart notes, laboratory values, etc.) confirming asthma is an eosinophilic phenotype as defined by a baseline (pre-treatment) peripheral blood eosinophil level  $\geq 150$  cells/ $\mu$ L

-AND-

- (d) Nucala will be used in combination with **one** of the following:

- i. **One** maximally dosed (appropriately adjusted for age) combination inhaled corticosteroid (ICS)/long-acting beta<sub>2</sub> agonist (LABA) [e.g., Advair/AirDuo Resplick (fluticasone propionate/salmeterol), Symbicort (budesonide/formoterol), Breo Ellipta (fluticasone furoate/vilanterol)]

-OR-

- ii. Combination therapy including **both** of the following:

- **One** maximally dosed (appropriately adjusted for age) ICS product [e.g., ciclesonide (Alvesco), mometasone furoate (Asmanex), beclomethasone dipropionate (QVAR)]
- **One** additional asthma controller medication [e.g., LABA - olodaterol (Striverdi) or indacaterol (Arcapta); leukotriene receptor antagonist – montelukast (Singulair); theophylline]

-AND-

- (e) Patient is not receiving Nucala in combination with **any** of the following for treatment of the same indication:

- i. Anti-interleukin 5 therapy [e.g., Cinqair (reslizumab), Fasenna (benralizumab)]
- ii. Anti-IgE therapy [e.g., Xolair (omalizumab)]
- iii. Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
- iv. Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

-AND-

- (f) Prescribed by **one** of the following:

- i. Allergist
- ii. Immunologist
- iii. Pulmonologist

**Authorization will be issued for 12 months.**

## **2. Reauthorization**

- a. **Nucala** will be approved based on **all** of the following criteria:
- (1) Documentation of positive clinical response to Nucala therapy as demonstrated by at least **one** of the following:
    - (a) Reduction in the frequency of exacerbations
    - (b) Decreased utilization of rescue medications
    - (c) Increase in percent predicted FEV1 from pretreatment baseline
    - (d) Reduction in severity or frequency of asthma-related symptoms (e.g., wheezing, shortness of breath, coughing, etc.)
    - (e) Reduction in oral corticosteroid requirements

-AND-

- (2) Nucala is being used in combination with an ICS-containing maintenance medication [e.g., Advair/AirDuo (fluticasone/salmeterol), Breo Ellipta (fluticasone furoate/vilanterol), Symbicort (budesonide/ formoterol), Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)].

-AND-

- (3) Patient is not receiving Nucala in combination with **any** of the following for treatment of the same indication:
  - (a) Anti-interleukin-5 therapy [e.g., Cinqair (reslizumab), Fasenna (benralizumab)]
  - (b) Anti-IgE therapy [e.g., Xolair (omalizumab)]
  - (c) Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]
  - (d) Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

**Authorization will be issued for 12 months.**

## C. Hypereosinophilic Syndrome (HES)

### 1. Initial Authorization

- a. **Nucala** will be approved based on **one** of the following criteria:
- (1) **All** of the following:
    - (a) Patient has been established on therapy with Nucala under an active UnitedHealthcare medical benefit prior authorization for the treatment of HES

-AND-

- (b) Documentation of positive clinical response to Nucala therapy as demonstrated by at least **one** of the following:

- i. Reduction in frequency of HES flares
- ii. Maintenance or reduction in background HES therapy requirements

-AND-

- (c) Patient is not receiving Nucala in combination with **any** of the following for treatment of the same indication:

- i. Anti-interleukin-5 therapy [e.g., Cinqair (reslizumab), Fasenra (benralizumab)]
- ii. Anti-IgE therapy [e.g., Xolair (omalizumab)]
- iii. Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]
- iv. Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

-AND-

- (d) Prescribed by **one** of the following:

- i. Allergist
- ii. Immunologist
- iii. Hematologist
- iv. Cardiologist
- v. Pulmonologist

-OR-

- (2) All of the following:

- (a) Diagnosis of HES  $\geq$  6 months ago

-AND-

- (b) **Both** of the following:

- i. There is no identifiable non-hematologic secondary cause of the patient's HES (e.g., drug hypersensitivity, parasitic helminth infection, HIV infection, non-hematologic malignancy)
- ii. HES is not FIP1L1-PDGFR $\alpha$  kinase-positive

-AND-

- (c) Submission of medical records (e.g., chart notes, laboratory values, etc.) documenting **both** of the following:

- i. Baseline (pre-mepolizumab treatment) blood eosinophil level  $\geq$ 1000 cells/ $\mu$ L within the past 4 weeks

- ii. Patient is currently receiving a stable dose of background HES therapy (e.g., oral corticosteroid, immunosuppressor, or cytotoxic therapy)

-AND-

- (d) Patient is not receiving Nucala in combination with **any** of the following for treatment of the same indication:

- i. Anti-interleukin-5 therapy [e.g., Cinqair (reslizumab), Fasenna (benralizumab)]
- ii. Anti-IgE therapy [e.g., Xolair (omalizumab)]
- iii. Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]
- iv. Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

-AND-

- (e) Prescribed by **one** of the following:

- i. Allergist
- ii. Immunologist
- iii. Hematologist
- iv. Cardiologist
- v. Pulmonologist

**Authorization will be issued for 12 months.**

## **2. Reauthorization**

- a. **Nucala** will be approved based on **both** of the following criteria:

- (1) Documentation of positive clinical response to Nucala therapy as demonstrated by at least **one** of the following:

- (a) Reduction in frequency of HES flares
- (b) Maintenance or reduction in background HES therapy requirements

-AND-

- (2) Patient is not receiving Nucala in combination with **any** of the following for treatment of the same indication:

- (a) Anti-interleukin-5 therapy [e.g., Cinqair (reslizumab), Fasenna (benralizumab)]
- (b) Anti-IgE therapy [e.g., Xolair (omalizumab)]
- (c) Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]
- (d) Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

**Authorization will be issued for 12 months.**

**D. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)**

**1. Initial Authorization**

a. **Nucala** will be approved based on **one** of the following criteria:

(1) **All** of the following:

(a) Patient has been established on therapy with Nucala under an active UnitedHealthcare medical benefit prior authorization for the treatment of CRSwNP

-AND-

(b) Documentation of positive clinical response to Nucala therapy

-AND-

(c) Patient will continue to receive Nucala as add-on maintenance therapy in combination with intranasal corticosteroids (e.g., fluticasone, mometasone, triamcinolone).

-AND-

(d) Patient is **not** receiving Nucala in combination with **any** of the following for treatment of the same indication:

- i. Anti-interleukin-5 therapy [e.g., Cinqair (reslizumab), Fasentra (benralizumab)]
- ii. Anti-IgE therapy [e.g., Xolair (omalizumab)]
- iii. Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]
- iv. Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

-AND-

(e) Prescribed by **one** of the following:

- i. Allergist
- ii. Immunologist
- iii. Otolaryngologist
- iv. Pulmonologist

-OR-

(2) **All** of the following:

(a) Diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP) defined by **all** of the following:

i. **Two or more** of the following symptoms for longer than 12 weeks duration:

- Nasal mucopurulent discharge
- Nasal obstruction, blockage, or congestion
- Facial pain, pressure, and/or fullness
- Reduction or loss of sense of smell

-AND-

ii. **One** of the following findings using nasal endoscopy and/or sinus computed tomography (CT):

- Purulent mucus or edema in the middle meatus or ethmoid regions
- Polyps in the nasal cavity or the middle meatus
- Radiographic imaging demonstrating mucosal thickening or partial or complete opacification of paranasal sinuses

-AND-

iii. **One** of the following:

- Presence of bilateral nasal polyposis
- Patient has previously required surgical removal of bilateral nasal polyps

-AND-

iv. **One** of the following:

- Patient has required prior sinus surgery
- Patient has required systemic corticosteroids (e.g., prednisone, methylprednisolone) for CRSwNP in the previous 2 years
- Patient has been unable to obtain symptom relief after trial of **two** of the following classes of agents:
  - Nasal saline irrigations
  - Intranasal corticosteroids (e.g., fluticasone, mometasone, triamcinolone)
  - Antileukotriene agents (e.g., montelukast, zafirlukast, zileuton)

-AND-

(b) Patient will receive Nucala as add-on maintenance therapy in combination with intranasal corticosteroids (e.g., fluticasone, mometasone, triamcinolone)

-AND-

(c) Patient is **not** receiving Nucala in combination with **any** of the following for treatment of the same indication:

i. Anti-interleukin 5 therapy [e.g., Cinqair (reslizumab), Fasenna (benralizumab)]

- ii. Anti-IgE therapy [e.g., Xolair (omalizumab)]
- iii. Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
- iv. Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

-AND-

(d) Prescribed by **one** of the following:

- i. Allergist
- ii. Immunologist
- iii. Otolaryngologist
- iv. Pulmonologist

**Authorization will be issued for 12 months.**

## **2. Reauthorization**

a. **Nucala** will be approved based on **all** of the following criterion:

(1) Documentation of positive clinical response to Nucala therapy

-AND-

(2) Patient will continue to receive Nucala as add-on maintenance therapy in combination with intranasal corticosteroids (e.g., fluticasone, mometasone, triamcinolone).

-AND-

(3) Patient is **not** receiving Nucala in combination with **any** of the following for treatment of the same indication:

- (a) Anti-interleukin-5 therapy [e.g., Cinqair (reslizumab), Fasentra (benralizumab)]
- (b) Anti-IgE therapy [e.g., Xolair (omalizumab)]
- (c) Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]
- (d) Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

**Authorization will be issued for 12 months.**

## **E. Chronic Obstructive Pulmonary Disease (COPD)**

### **1. Initial Authorization**

a. **Nucala** will be approved based on **one** of the following criteria:

(1) **All** of the following:

- (a) Patient has been established on therapy with Nucala under an active UnitedHealthcare medical benefit prior authorization for the treatment of COPD

-AND-

- (b) Documentation of positive clinical response to Nucala therapy

-AND-

- (c) Patient will continue to receive Nucala as add-on maintenance therapy

-AND-

- (d) Patient is not receiving Nucala in combination with **any** of the following for treatment of the same indication:

- i. Anti-interleukin 5 therapy [e.g., Cinqair (reslizumab), Fasenna (benralizumab)]
- ii. Anti-IgE therapy [e.g., Xolair (omalizumab)]
- iii. Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
- iv. Thymic stromal lymphopoietin (TSLP) inhibitor therapy [e.g., Tezspire (tezepelumab)]

-OR-

- (2) **All** of the following:

- (a) Diagnosis of COPD

-AND-

- (b) Submission of medical records (e.g., chart notes) documenting **all** of the following:

- i. Post-bronchodilator forced expiratory volume (FEV<sub>1</sub>) / forced vital capacity (FVC) ratio less than 0.7
- ii. Post-bronchodilator FEV<sub>1</sub> % predicted greater than or equal to 20% and less than or equal to 80%
- iii. Patient has an eosinophilic phenotype defined by a baseline (pre-mepolizumab treatment) peripheral blood eosinophil level  $\geq$  300 cells/ $\mu$ L

-AND-

- (c) Uncontrolled or inadequately controlled COPD demonstrated by **both** of the following:

- i. **One** of the following:

- Two or more COPD exacerbations in the previous year requiring treatment with systemic corticosteroids and/or antibiotics
- One or more COPD exacerbation(s) that resulted in hospitalization or observation for over 24 hours in an emergency department or urgent care facility in the past year

-AND-

- ii. COPD exacerbation(s) occurred while receiving maintenance therapy with one of the following:
- Triple therapy with a long-acting muscarinic antagonist (LAMA), long-acting beta agonist (LABA), and inhaled corticosteroid (ICS) (e.g., Breztri Aerosphere, Trelegy Ellipta)
  - Dual therapy with a LAMA and LABA (e.g., Anoro Ellipta, Bevespi Aerosphere, Stiolto Respimat) and a failure, contraindication, or intolerance to an inhaled corticosteroid (ICS)

-AND-

- (d) Nucala will be used as add-on maintenance therapy in combination with one of the following:
- i. Triple therapy with a long-acting muscarinic antagonist (LAMA), long-acting beta agonist (LABA), and inhaled corticosteroid (ICS) (e.g., Breztri Aerosphere, Trelegy Ellipta)
- ii. Dual therapy with a LAMA and LABA (e.g., Anoro Ellipta, Bevespi Aerosphere, Stiolto Respimat) and a failure, contraindication, or intolerance to an inhaled corticosteroid (ICS)

-AND-

- (f) Patient is not receiving Nucala in combination with any of the following for treatment of the same indication:
- i. Anti-interleukin-5 therapy [e.g., Cinqair (reslizumab), Fasenna (benralizumab)]
- ii. Anti-IgE therapy [e.g., Xolair (omalizumab)]
- iii. Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]
- iv. Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezpelumab)]

-AND-

- (g) Prescribed by one of the following:
- i. Allergist
- ii. Immunologist
- iii. Pulmonologist

**Authorization will be issued for 12 months.**

**2. Reauthorization**

a. **Nucala** will be approved based on **all** of the following criteria:

- (1) Documentation of a positive clinical response to Nucala therapy as demonstrated by at least **one** of the following:
  - (a) Reduction in the frequency of COPD exacerbations
  - (b) Increase in percent predicted FEV1 from pretreatment baseline
  - (c) Reduction in severity or frequency of COPD-related symptoms (e.g., dyspnea, wheezing, cough, sputum volume, decrease in sputum purulence)
  - (d) Reduction in oral corticosteroid requirements

**-AND-**

- (2) Nucala is being used as add-on maintenance therapy in combination with **one** of the following:
  - (a) Triple therapy with a long-acting muscarinic antagonist (LAMA), long-acting beta agonist (LABA), and inhaled corticosteroid (ICS) (e.g., Breztri Aerosphere, Trelegy Ellipta)
  - (b) Dual therapy with a long-acting muscarinic antagonist (LAMA) and long-acting beta agonist (LABA) (e.g., Anoro Ellipta, Bevespi Aerosphere, Stiolto Respimat) and a failure, contraindication, or intolerance to an inhaled corticosteroid (ICS)

**-AND-**

- (3) Patient is not receiving Nucala in combination with **any** of the following for treatment of the same indication:
  - (a) Anti-interleukin-5 therapy [e.g., Cinqair (reslizumab), Fasenna (benralizumab)]
  - (b) Anti-IgE therapy [e.g., Xolair (omalizumab)]
  - (c) Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]
  - (d) Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]

**-AND-**

- (4) Prescribed by **one** of the following:
  - (a) Allergist
  - (b) Immunologist
  - (c) Pulmonologist

**Authorization will be issued for 12 months.**

<sup>a</sup> State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply.

### 3. Additional Clinical Programs:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Supply limitations may be in place.
- Medical Necessity may be in place.
- The single-dose vial is typically covered under the medical benefit. Please refer to the United Healthcare Medical Benefit Drug Policy: “Respiratory Interleukins (Cinqair<sup>®</sup>, Fasentra<sup>®</sup>, and Nucala<sup>®</sup>)”.

### 4. References:

1. Nucala<sup>®</sup> [package insert]. Philadelphia, PA: GlaxoSmithKline, LLC; May 2025.
2. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J*. 2014 Feb;43(2):343-73.
3. Institute for Clinical and Economic Review (ICER). Mepolizumab (Nucala<sup>®</sup>, GlaxoSmithKline plc.) for the Treatment of Severe Asthma with Eosinophilia: Effectiveness, Value, and Value-Based Price Benchmarks. March 14, 2016. Available at <http://icer-review.org/material/asthma-final-report/>. Accessed May 2024.
4. Global Initiative for Asthma. Difficult-To-Treat & Severe Asthma in adolescent and adult patients. Diagnosis and Management, 2024. Available at <http://www.ginasthma.org>. Accessed May 29, 2025.
5. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, et al. Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma. *New Eng J Med*. 2014 Sept;371(13):1189-97.
6. Parameswaran KN, Dasgupta A, et al. Mepolizumab in COPD with Eosinophilic Bronchitis: A Randomized Clinical Trial. Poster session presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology, Los Angeles, CA. March 2016.
7. Centers for Disease Control and Prevention. Asthma. Available at <http://www.cdc.gov/asthma/>. Accessed May 29, 2025.
8. National Heart, Lung and Blood Institute. Explore Asthma. Available at <http://www.nhlbi.nih.gov>. Accessed May 29, 2025.
9. Hypereosinophilic Syndrome (HES). American Academy of Allergy, Asthma & Immunology. Available at <https://www.aaaai.org>. Accessed May 29, 2025.
10. Roufousse F, Kahn J-E, Rothenberg ME, et al. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a Phase III, randomized, placebo-controlled trial. *Journal of Allergy and Clinical Immunology*. September 2020.
11. Roufousse F, Klion A, Weller P. Hypereosinophilic syndromes: Treatment. Updated November 30, 2022. Accessed May 29, 2025.
12. Peters AT, Spector S, Hsu J, et al. Diagnosis and management of rhinosinusitis: a practice parameter update. *Ann Allergy Asthma Immuno*. 2014;113:347-385.
13. Han JK, Bachert C, Fokkens W, et al. SYNAPSE study investigators. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled,

phase 3 trial. *Lancet Respir Med.* 2021 Apr 16;S2213-2600(21)00097-7. doi: 10.1016/S2213-2600(21)00097-7. Epub ahead of print.

14. Buchheit KM, Holbrook EH. Chronic rhinosinusitis with nasal polyposis: Management and prognosis. UpToDate. Waltham, MA: UpToDate Inc. <https://www.uptodate.com>. Updated April 24, 2025. Accessed on May 29, 2025.
15. Holguin F, Cardet JC, Chung KF, et al.. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. *Eur Respir J.* 2020 Jan 2;55(1):1900588. doi: 10.1183/13993003.00588-2019.
16. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2026 Report. [www.goldcopd.org](http://www.goldcopd.org) Accessed on November 19, 2025.

Program	Prior Authorization/Medical Necessity - Nucala (mepolizumab)
<b>Change Control</b>	
8/2019	New program.
4/2020	Updated program to address specific product formulations. Updated references.
8/2020	Annual review. Updated background and references.
3/2021	Updated program to add HES indication. Added limitations of use. Updated references.
6/2021	Added criteria if patient has been approved and received initial dose of Nucala directly monitored by a healthcare professional without reaction.
9/2021	Added coverage criteria for new indication, chronic rhinosinusitis with nasal polyps. Updated background and references.
11/2021	Added coverage criteria for patients established on therapy under UnitedHealthcare medical benefit. Removed prescriber requirement for reauthorization.
2/2022	Added Tezspire to list of agents not to be used in combination with Nucala for all indications. Updated coverage criteria for CRSwNP. Updated references. Added footnote to support FDA labeled first line requirements.
6/2022	Added pulmonologist to list of appropriate prescribers in section for patients established on therapy with Nucala for CRSwNP.
6/2023	Annual review. Updated examples of standard therapy for EGPA and added examples of oral corticosteroids within Asthma criteria. Updated background and references.
7/2023	Updated EGPA standard therapy examples. Updated coverage criteria for severe asthma to align with GINA & ERS/ATS guidelines. Added/updated examples of ICS-containing maintenance medications, removed requirement that peripheral blood eosinophil level must be within 6 weeks, and removed bypass of eosinophilic phenotype requirement for patients currently dependent on maintenance therapy with oral corticosteroids. Updated references.
7/2024	Annual review. Updated background with modified indication for CRSwNP. Specified existing prior authorization for under the medical benefit. Updated references.

7/2025	Annual review. Added new indication and criteria for chronic obstructive pulmonary disorder. Updated statement on concomitant use throughout. Updated background and reference.
12/2025	Updated criteria for COPD by removing criteria requiring symptoms of a chronic productive cough and updating post-bronchodilator FEV1 % predicted from 'greater than or equal to 30% and less than or equal to 70%' to 'greater than or equal to 20% and less than or equal to 80%'. Updated references.